# Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis

> **NCT04129736** · PHASE4 · COMPLETED · sponsor: **Jan Lycke** · enrollment: 12 (actual)

## Conditions studied

- Multiple Sclerosis, Pharmacokinetics

## Interventions

- **DRUG:** Teriflunomide 14 MG

## Key facts

- **NCT ID:** NCT04129736
- **Lead sponsor:** Jan Lycke
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-10
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-06-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129736, "Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04129736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*